FDA panel to weigh Myozyme expansion

The FDA questions whether a study submitted by Genzyme is strong enough to merit expanded approval of a drug to treat a rare illness known as Pompe disease; the drug, Myozyme, is up for advisory committee discussion tomorrow. Report

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.